非小细胞肺癌 XRCC1Arg399Gln 基因分析与顺铂疗效的关系.

Objective To investigate the relationship between XRCC1 Arg399 Gln polymorphisms and the efficacy of platinum-based chemotherapy in non-small cell lung cancer （NSCLC） . Methods Eighty-three patients with NSCLC treated with platinum-based chemotherapy were enrolled in this study and their tumor samples were collected retrospectively for analysis. The polymorphisms of XRCC1 Arg399 Gln in NSCLC were detected by polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP), and the data were collected and analyzed. Results Of all cases, the frequencies of XRCC1 codon 399 Arg /Arg, Arg /Gln and Gln /Gln genotype were 59.04%，33.73% and 7.23%，respectively. The response rate to therapy in patients with XRCC1 codon 399 Arg /Arg genotype （42.86%） was significantly higher than that in patients with the Arg /Gln and Gln/Gln genotype （11.76%). The response rate to therapy in patients with XRCC1 codon 399 Arg/Arg genotypes was significantly higher than that in patients with other XRCC1 genotypes. XRCC1 genotypes had no significant correlation with the side effects of chemotherapy. Conclusion It has certain relationships between the polymorphisms of XRCC1 Arg399 Gln and platinum-based chemotherapy in NSCLC， and the patients with XRCC1 399Arg/Arg are more conducive to use platinum-based chemotherapy. The results can provide some basis for clinical medication. [ABSTRACT FROM AUTHOR]